Utah Medical Products (UTMD) EV to EBITDA (2010 - 2026)

Utah Medical Products has reported EV to EBITDA for 17 years, with the latest figure at 49.84 in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 57.92% year-over-year to 49.84 in Q2 2026; TTM through Jun 2026 was 12.86, a 60.93% increase from a year earlier, with the FY2025 full-year figure at 8.12, down 9.59% from the prior year.
• EV to EBITDA was 49.84 for Q2 2026 at Utah Medical Products, up from 42.87 in the prior quarter.
• The five-year high for EV to EBITDA was 59.23 in Q1 2023, with the low at 31.56 in Q2 2025.
• Average EV to EBITDA over 5 years is 46.88, with a median of 45.82 recorded in 2025.
• The sharpest annual moves came in 2024 and 2026: EV to EBITDA slipped 29.85% in 2024, then soared 57.92% in 2026.
• Over 5 years, EV to EBITDA stood at 57.13 in 2022, then fell by 5.62% to 53.93 in 2023, then decreased by 22.77% to 41.65 in 2024, then decreased by 8.98% to 37.91 in 2025, then jumped by 31.49% to 49.84 in 2026.
• The last three EV to EBITDA figures came in at 49.84 (Q2 2026), 42.87 (Q1 2026), and 37.91 (Q4 2025), per Business Quant data.